secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2023-12-06T23:59:59+00:00
Accession:  0001193125-23-289922
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Neoleukin faces 3 stockholder suits over Neurogene merger; issues supplemental disclosures
--------------------------------------------------------------------------------

- Three lawsuits and ten demands received from stockholders challenging the merger and proxy disclosures.
- Company denies any legal violations but provides supplemental disclosures to avoid litigation disruption.
- Supplemental disclosures amend sections on Transaction Committee composition, valuation DCF, and selected public company analyses.
- DCF implied Neurogene equity value of $445M-$560M; selected companies analysis with 20% illiquidity discount used.
- Executive officers Sean Smith and Donna Cochener entered post-merger consulting negotiations for transition and CVR matters.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000119312523289922/0001193125-23-289922-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000119312523289922/d98332d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-289922

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer